Intermountain Healthcare Names Mandy Richards New Chief Nursing Executive

Mandy Richards, MSN, RN, APRN, ACNS-BC, NEA-BC, has been named as the chief nursing executive (CNE) for Intermountain Healthcare and will serve as a member of the Enterprise Leadership Team.

Mandy Richards has built a distinguished career in executive nursing, coming to Intermountain from Hartford HealthCare in Hartford, Connecticut where she has served as the executive vice president and chief nursing officer over the past two years. Before her time in Connecticut, she spent 15 years with Allina Health in Minneapolis, Minnesota where she served in ever-expanding leadership roles, and ultimately as the chief nursing officer for the health system. In her time with Allina, Richards served as the CNO and VP of Patient Care and VP of Clinical Operations for multiple hospitals within the system.

Mandy Richards completed a Master of Science in Nursing from the University of Technology in Sydney, Australia and a mini-MBA from the University of St. Thomas in Minneapolis She also received her Bachelor of Science in Nursing from Deakin University in Melbourne, Australia. She is currently pursuing a Doctor of Nursing Practice from Yale University in New Haven, Connecticut.

“This is a pivotal leadership position for Intermountain,” said JP Valin, MD, chief clinical officer at Intermountain Healthcare. “Mandy’s expertise will support our continued focus on providing the best possible experience for our nurses. We’re thrilled to have her on board.”

Richards will join Intermountain on January 2, 2023.

Headquartered in Utah with locations in eight states and additional operations across the western U.S., Intermountain Healthcare is a nonprofit system of 33 hospitals, 385 clinics, medical groups with some 3,900 employed physicians and advanced care providers, a health plans division called SelectHealth with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”